- Email: [email protected]
4483928 Microcapsules sensitized with antibody and a method for measurement of lymphocyte using the same based on cellmediated immunity
Comp. Immun. Microbiol. infect. Dis. Vol. 8, No. 1, pp. i-vii, 1985 Pergamon Press Ltd. Printed in Great Britain
NEW PATENTS This Section contains abstracts and, where appropriate, illustrations of recently issued United States patents and published patent applications filed from over 30 countries under the Patent Cooperation Treaty. This information was obtained from recent additions to the Pergamon PATSEARCH k online database in accordance with interest profiles developed by the Editors. Further information about Pergamon PATSEARCH * can be obtained from Pergamon InfoLine Inc., 1340 Old Chain Bridge Road, McLean, Virginia 22101 U.S.A. Copies of complete patents announced in this Section are available from Pergamon lnfoLine Inc. for $8 per copy. Payment with order is required. Orders outside North America add $2 for air postage. Order by patent number for Pergamon lnfoLine only.
4483793
4483921
DIMERIC OLIGOPEPTIDES A ~ HEPTENIC EPITOPIC SITES FOR HEPATITIS
IMMUNOASSAY WITH ANTIGEN OR ANTIBODY LABELED LIPOSOMES SEQUESTERING ENZYME
Girish N Vyas assigned to The Regents of the University of California Methods and compositions concerned with the a determinant of hepatitis B antigen, providing immunogens and antibodies. The immunogens can serve as vaccines.
4483849 STABILIZATION AND PURIFICATION OF INTERFERON WITH PROPYLENE GLYCOL, RESULTING IN A NON-TOXIC PRODUCT William A Carter, Geral Silver A new process for stabilizing purified human interferon is described, using propylene glycol. Propylene glycol also aids in the interferon purification procedure. Older methods used stabilizing agents which are toxic, antigenic or irritating. The new process will make available significantly more interferon of clinical purity for use in patients with cancer, viral illnesses and other diseases as yet undesignated (e.g. multiple sclerosis, amyotropic lateral sclerosis, seleroderma, etc.).
Francis X Cole assigned to Collaborative Research Inc An immunoassay method utilizes antigen tagged, enzyme encapsulating liposomes which are immunospecificaily ruptured in the presence of cognate antibody and active complement. A homogeneous phase reaction occurs with the antibody and complement acting to release the enzyme if an immunospecific antigen-antibody complex is formed at the surface of the liposome. The positions of the antigen and antibody can be reversed.
4483928 MICROCAPSULES SENSITIZED WITH ANTIBODY AND A METHOD FOR MEASUREMENT OF LYMPHOCYTE USING THE SAME BASED ON CELLMEDIATED IMMUNITY Tatsuo Suzuta, Nobuo Hiratsuka, Tokyo, Japan assigned to Fuji Photo Film Co Ltd Microcapsules are sensitized with antibody to antigen of lymphocyte. Using such microcapsules, B cells and/or T cells can be selectively measured separately or simultaneously, in a simple manner, based on cell-mediated immunity which comprises applying the microcapsules
New Patents
sensitized with antibody to antigen of lymphocyte and sheep red cells or another kind of antibody-sensitized microcapsules that are optically distinguishable from the first antibodysensitized microcapsules, to lymphocyte at the same time and thereafter independently measuring respective cells that are optically distinguishable from each other. The operation for the measurement is extremely simple and neither skill nor special equipment is required.
I I~*-
i
u !i
'i !i } !
~t
=
!i
} i""
r'i,,
4483929 LIPOSOMES WITH GLYCOLIPIDLINKED ANTIBODIES Frank C Szoka assigned to Liposome Technology Incorporated Lipid vesicles, labelled with encapsulated reporter compositions and bound to antibodies comprise a new class of immunoreagent, useful in immunoassays for ligands.
An improved process for the isolation and purification of HIFNs is disclosed wherein a partially purified preparation of the HIFN is sequentially passed through an antibody affinity column and a reversed-phase high performance liquid chromatographic column. Organic solvents used during the elution are extracted and the protein concentrated for subsequent use.
4485093 4484923 METHOD FOR ADMINISTERING IMMUNOPOTENTIATOR Alfred Amkraut, Agusto Martins assigned to ALZA Corporation
IMMUNOTOXIN CONJUGATE WHICH COMPRISES ARSANILIC ACID, USEFUL FOR TREATING MALIGNANT TUMORS, PARTICULARLY PANCREATIC CANCER Richard G Runge
The invention pertains to the administration of an immunopotentiator to activate an immune t:esponse. The administration comprises the controlled and continuous administration of the immunopotentiator leading to a high immune response with adequate persistancy, while simultaneously and substantially reducing or eliminating inflammatory reactions usually accompanying depot-type administration.
An immunotoxin conjugate, useful for treating malignant tumors in mammals, which consists of arsanilic acid and tumor specific antibodies covalently bound to a polyglutamic acid linking agent is taught. The conjugate selectively delivers arsanilic acid to a tumor, killing the tumor cells and exhibiting little or no toxicity to normal cells. The conjugate is effective in treating human pancreatic cancer.
4485175
4485017 ISOLATION OF HUMAN INTERFERON BY IMMUNOSORBENT AND HIGH PERFORMANCE LIQUID CHROMATOGRAPHY
METHOD FOR THREE-VOLUME DIFFERENTIAL DETERMINATION OF LYMPHOCYTE, MONOCYTE AND GRANULOCYTE POPULATIONS OF LEUKOCYTES
Yin H Tan, Heidi Smith-Johannsen, Calgary, Canada assigned to Cetus Corporation
Stephen Ledis, Ted Sena, Harold Crews, James H Carter assigned to Coulter Electronics Inc
NEW PATENTS This Section contains abstracts and, where appropriate, illustrations of recently issued United States patents and published patent applications filed from over 30 countries under the Patent Cooperation Treaty. This information was obtained from recent additions to the Pergamon PATSEARCH k online database in accordance with interest profiles developed by the Editors. Further information about Pergamon PATSEARCH * can be obtained from Pergamon InfoLine Inc., 1340 Old Chain Bridge Road, McLean, Virginia 22101 U.S.A. Copies of complete patents announced in this Section are available from Pergamon lnfoLine Inc. for $8 per copy. Payment with order is required. Orders outside North America add $2 for air postage. Order by patent number for Pergamon lnfoLine only.
4483793
4483921
DIMERIC OLIGOPEPTIDES A ~ HEPTENIC EPITOPIC SITES FOR HEPATITIS
IMMUNOASSAY WITH ANTIGEN OR ANTIBODY LABELED LIPOSOMES SEQUESTERING ENZYME
Girish N Vyas assigned to The Regents of the University of California Methods and compositions concerned with the a determinant of hepatitis B antigen, providing immunogens and antibodies. The immunogens can serve as vaccines.
4483849 STABILIZATION AND PURIFICATION OF INTERFERON WITH PROPYLENE GLYCOL, RESULTING IN A NON-TOXIC PRODUCT William A Carter, Geral Silver A new process for stabilizing purified human interferon is described, using propylene glycol. Propylene glycol also aids in the interferon purification procedure. Older methods used stabilizing agents which are toxic, antigenic or irritating. The new process will make available significantly more interferon of clinical purity for use in patients with cancer, viral illnesses and other diseases as yet undesignated (e.g. multiple sclerosis, amyotropic lateral sclerosis, seleroderma, etc.).
Francis X Cole assigned to Collaborative Research Inc An immunoassay method utilizes antigen tagged, enzyme encapsulating liposomes which are immunospecificaily ruptured in the presence of cognate antibody and active complement. A homogeneous phase reaction occurs with the antibody and complement acting to release the enzyme if an immunospecific antigen-antibody complex is formed at the surface of the liposome. The positions of the antigen and antibody can be reversed.
4483928 MICROCAPSULES SENSITIZED WITH ANTIBODY AND A METHOD FOR MEASUREMENT OF LYMPHOCYTE USING THE SAME BASED ON CELLMEDIATED IMMUNITY Tatsuo Suzuta, Nobuo Hiratsuka, Tokyo, Japan assigned to Fuji Photo Film Co Ltd Microcapsules are sensitized with antibody to antigen of lymphocyte. Using such microcapsules, B cells and/or T cells can be selectively measured separately or simultaneously, in a simple manner, based on cell-mediated immunity which comprises applying the microcapsules
New Patents
sensitized with antibody to antigen of lymphocyte and sheep red cells or another kind of antibody-sensitized microcapsules that are optically distinguishable from the first antibodysensitized microcapsules, to lymphocyte at the same time and thereafter independently measuring respective cells that are optically distinguishable from each other. The operation for the measurement is extremely simple and neither skill nor special equipment is required.
I I~*-
i
u !i
'i !i } !
~t
=
!i
} i""
r'i,,
4483929 LIPOSOMES WITH GLYCOLIPIDLINKED ANTIBODIES Frank C Szoka assigned to Liposome Technology Incorporated Lipid vesicles, labelled with encapsulated reporter compositions and bound to antibodies comprise a new class of immunoreagent, useful in immunoassays for ligands.
An improved process for the isolation and purification of HIFNs is disclosed wherein a partially purified preparation of the HIFN is sequentially passed through an antibody affinity column and a reversed-phase high performance liquid chromatographic column. Organic solvents used during the elution are extracted and the protein concentrated for subsequent use.
4485093 4484923 METHOD FOR ADMINISTERING IMMUNOPOTENTIATOR Alfred Amkraut, Agusto Martins assigned to ALZA Corporation
IMMUNOTOXIN CONJUGATE WHICH COMPRISES ARSANILIC ACID, USEFUL FOR TREATING MALIGNANT TUMORS, PARTICULARLY PANCREATIC CANCER Richard G Runge
The invention pertains to the administration of an immunopotentiator to activate an immune t:esponse. The administration comprises the controlled and continuous administration of the immunopotentiator leading to a high immune response with adequate persistancy, while simultaneously and substantially reducing or eliminating inflammatory reactions usually accompanying depot-type administration.
An immunotoxin conjugate, useful for treating malignant tumors in mammals, which consists of arsanilic acid and tumor specific antibodies covalently bound to a polyglutamic acid linking agent is taught. The conjugate selectively delivers arsanilic acid to a tumor, killing the tumor cells and exhibiting little or no toxicity to normal cells. The conjugate is effective in treating human pancreatic cancer.
4485175
4485017 ISOLATION OF HUMAN INTERFERON BY IMMUNOSORBENT AND HIGH PERFORMANCE LIQUID CHROMATOGRAPHY
METHOD FOR THREE-VOLUME DIFFERENTIAL DETERMINATION OF LYMPHOCYTE, MONOCYTE AND GRANULOCYTE POPULATIONS OF LEUKOCYTES
Yin H Tan, Heidi Smith-Johannsen, Calgary, Canada assigned to Cetus Corporation
Stephen Ledis, Ted Sena, Harold Crews, James H Carter assigned to Coulter Electronics Inc